XML 38 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based Compensation
 9 Months Ended
Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation Stock-based Compensation

Stock Incentive Plan
The Company has a stock incentive plan, the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”) that provides for the granting of stock options, restricted stock units (RSUs), performance stock options (PSOs), and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan. There were no significant modifications to the Plan during the nine months ended September 30, 2019 or 2018.
Stock-based compensation expense included in the condensed consolidated statements of comprehensive loss was $3.2 million, and $1.7 million for the three months ended September 30, 2019 and 2018, respectively, and $7.3 million and $4.4 million for the nine months ended September 30, 2019 and 2018.

The following table summarizes the activity for stock options, RSUs and PSOs for the nine months ended September 30, 2019 (in thousands):
 
Stock Options
 
RSUs
 
PSOs
Equity awards outstanding, beginning of year
4,757

 
15

 
538
   Changes during the year:
 
 
 
 
 
   Granted
3,305

 
58

 
650

   Exercised
(1,164
)
 
(15
)
 
—

   Expired or forfeited
(1,168
)
 
—

 
(493
)
Equity awards outstanding, end of period
5,730

 
58

 
695

On March 14, 2019, performance stock options were granted to certain individuals that vest upon the Company’s receipt of approval from the FDA for the Company’s BLA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. There were additional stock options that were granted to certain eligible individuals that vest on the second anniversary of the date of grant. In addition, on April 17, 2019 performance stock options were granted to certain individuals that vest upon achievement of defined sales performance milestones.

As of September 30, 2019, total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized were as follows ($ in thousands):
 
Stock Options
 
RSUs
 
PSOs
Unrecognized compensation cost
$
41,872

 
$
512

 
$
4,791

Expected weighted-average period in years of compensation cost to be recognized
3.2

 
0.7

 
1.0